Biotech, Food & Drug

HB Ad Slot
HB Mobile Ad Slot

In today’s hyper-aware environment, concerns about food and drug safety are paramount for both companies and consumers.  The Food and Drug Administration (FDA) and the US Department of Agriculture (USDA) regulates the areas of biotech, food, and drug law. Additionally, laws including the 21st Century Cures Act, and cGMP (Current Good Manufacturing Processes), regulate industry standards/norms in food, cosmetics, and other industry-sectors. Visitors to the National Law Review will find the latest analysis of news, legislation, and upcoming cases/litigation as it relates to this area of law.

With researchers searching for new energy solutions and other developments in biotech, visitors to the NLR will have the opportunity to read content surrounding biosimilars, natural fuel production, medical devices, biotechnology, nanotechnology and materials, and the pharmaceuticals industry. Additionally, content relating to food and drug laws, limits on chemical use in cosmetic products, and other general health/safety topics are covered by the National Law Review and are updated regularly. Additionally, food safety and imports to the United States are also discussed as they become relevant. 

In addition to general health, science, and food/drug, the industry is also closely related to many of the issues related to intellectual property law. New applications for patents, intellectual property, licensing laws, and other areas which are governed by the PTAB court, often crossover into the industry.

New developments in legislation, including the legalization of recreational marijuana has created a new area ripe for legal analysis.  Regulations on how recreational marijuana can be advertised and marketed, distributed and the kind of insurance coverage necessary for dispensaries.  Additionally, employer drug-testing and marijuana statutes have been a hot area of litigation covered by the National Law Review.  

General practices in marketing standards, compliance of federal and state laws/legislation, licensing collaborations, and news related to bringing new products to the market, in the US and abroad, are among the areas visitors to NLR will read about daily. Drug pricing, changes in production standards, regulatory compliance, food safety and handling, drug laws (legalization of marijuana, both recreational and medicinal in the workplace), and labeling and nutritional requirements, are among the many topics covered by the National Law Review daily.

Visitors will always find the latest, up-to-date, most comprehensive coverage on the site. And, news and stories which affect the US, companies which are regulated in the industry, and multinational/international companies, are detailed regularly for NLR readers.

National Law Review Cannabis TwitterFor hourly updates on the latest news about biotech, food & drug, and cannabis laws, regulations, and legislation, be sure to follow our Cannabis X (formerly Twitter) feed, and sign up for complimentary e-news bulletins.

Recent Biotechnology, Food & Drug Administration FDA News

Title
Publication Date Organization
May
18
2015
Are Cosmetics Gaining Higher Congressional and FDA Scrutiny? Mintz
May
14
2015
FDA Issues Guidance for Mobile Medical Apps McBrayer, McGinnis, Leslie and Kirkland, PLLC
May
14
2015
More Biosimilar Q&A’s Released by FDA - Food and Drug Administration Mintz
May
14
2015
Maker’s Mark Defeats “Handmade” Class Action Lawsuit McDermott Will & Emery
May
14
2015
Employer’s Use of DNA Test to Catch Employee Engaging in Inappropriate Workplace Behavior Violates Federal Law Mintz
May
14
2015
FDA Issues Final Guidance on Biosimilars ArentFox Schiff LLP
May
14
2015
First Look At False Marking Under The AIA - America Invents Act Foley & Lardner LLP
May
12
2015
FDA Releases Additional Guidelines for Biosimilars ArentFox Schiff LLP
May
12
2015
California Supreme Court Scrutinizes Reverse Payment ANDA Settlements Foley & Lardner LLP
May
11
2015
FDA Releases Draft Guidance on Using Clinical Data from Studies Conducted Outside the United States to Support Approval of Medical Devices Barnes & Thornburg LLP
May
11
2015
Amarin Pharma Preemptively Sues FDA over First Amendment Rights Barnes & Thornburg LLP
May
8
2015
Purdue Pharma v. Depomed: Denying Request for Rehearing Decision on Institution IPR2014-00379 Faegre Drinker
May
8
2015
CMS Issues Interim Final Rule Reaffirming Requirements for Prescribers of Part D Drugs McDermott Will & Emery
May
7
2015
CMS Amends Medicare Part D Program Integrity Regulations to Facilitate Beneficiary Access and Expand Coverage for Pharmacist Prescribers Epstein Becker & Green, P.C.
May
7
2015
A Court in the Sunshine State Blocks Injunctive Relief against Neutrogena Sunscreen Claims; Meanwhile P&G Cannot Flush Charmin Claims for the Same Relief in New York Proskauer Rose LLP
May
7
2015
340B ‘Mega-Guidance’ Arrives at Office of Management and Budget McDermott Will & Emery
May
6
2015
Study Suggests Skin Cancer Drug May Help Treat Mesothelioma and Lung Cancers Steptoe & Johnson PLLC
May
6
2015
FDA Issues Draft Guidance on Determining when Data from Foreign Clinical Studies Can Support Device Submissions Covington & Burling LLP
May
6
2015
Federal Circuit Keeps Sandoz Biosimilar Off The Market For Now Foley & Lardner LLP
May
5
2015
Keeping Up With Kyle Bass: Pharma Patents Post Foley & Lardner LLP
May
1
2015
FDA Finalizes Guidance Documents on Biosimilarity Sterne, Kessler, Goldstein & Fox P.L.L.C.
May
1
2015
Onward to Trial: Federal Court Rejects Vermont’s Motion to Dismiss GMA Lawsuit Mintz
May
1
2015
Petitioners Must Present Sufficient Evidence to Establish Inherency Mintz
Apr
30
2015
Tomorrow is Another One-A-Day: FDA Guidelines Preempt Vitamin Claims, but Consumer Class Still Has Opportunity to Supplement Proskauer Rose LLP
Apr
30
2015
Why the Grace Period Restoration Act Is a Bad Idea Foley & Lardner LLP
Apr
30
2015
UPDATE: FDA Speeds Up the BMPEA Battle ArentFox Schiff LLP
Apr
30
2015
FDA Finalizes Key Guidance Documents on Biosimilars Mintz
Apr
30
2015
Galderma and Q-Med AB v. Allergan: Decision on Institution of Inter Partes Review IPR2014-01417 Faegre Drinker
 

NLR Logo

We collaborate with the world's leading lawyers to deliver news tailored for you. Sign Up to receive our free e-Newsbulletins

 

Sign Up for e-NewsBulletins